Big blow in the United States by multinational biotechnology company Diasorin. The Italian diagnostics company, in fact, has collected the green light from the Food and Drug Administration to commercialize its new molecular diagnostics platform Liaison Plex and its first panel of tests on respiratory diseases - those on blood and gastrointestinal viruses will follow. The stock of the Saluggia-based group (Vercelli) celebrated at the start of the stock market by climbing more than 5 percent. The Liaison Plex is a machine that allows multiple pathogens to be processed on a single saliva or blood sample simultaneously, resulting in cost efficiency and speed for hospital laboratories. The FDA has cleared the first panel inherent in respiratory pathogens, with 19 viruses to be tested simultaneously. In this technique, French Biomeriuex is the market leader, but Diasorin now adds innovative elements to it, such as the "flex" technology: the physician can decide to test only the stock of viruses he or she needs, customizing the test panel, making it cheaper and faster, so much so that it takes only 2-3 minutes to get the result. The new product is intended for the U.S. market, and was successfully developed following the 2021 acquisition of Luminex, a Texas-based company specializing in this technology. Diasorin focuses on the hospital segment (where it serves 300 hospitals and aims for 500 by 2025) and now realizes about half of its sales across the Atlantic.
|